Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges.

Pharmaceutics

MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK.

Published: January 2023

Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the joint lining. In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866666PMC
http://dx.doi.org/10.3390/pharmaceutics15010237DOI Listing

Publication Analysis

Top Keywords

musculoskeletal disorders
12
musculoskeletal system
8
musculoskeletal
5
oligonucleotide therapeutics
4
therapeutics age-related
4
age-related musculoskeletal
4
disorders
4
disorders successes
4
successes challenges
4
challenges age-related
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!